Yatharth Hospital — Building Beds Faster Than the Cycle Can Punish

The State of Play

Yatharth runs a cluster of multi-specialty hospitals in and around Delhi NCR, built around the idea of putting tertiary-care beds where the population has outrun the hospital supply. Through FY26 it grew fast and spent fast: revenue rose 36% to ₹1,207 crore even as it opened two ~700-bed hospitals, bought a third in Agra, and announced a fourth in Gurugram — a deliberate strategy of adding capacity faster than the new-hospital losses can drag down the group. The reported numbers held up (FY26 EBITDA margin 24.2%, adjusted for new-unit gestation 28.5%), and the balance sheet has just begun to lever up after the cash from its 2023 IPO and a 2024 fund-raise ran down. The market prices it at about 44 times earnings, betting the bed-building keeps compounding.

The Company

Yatharth was incorporated in 2008 and listed in August 2023. It operates a network of multi- and super-specialty hospitals concentrated in Delhi NCR — Noida, Greater Noida, Noida Extension, two in Faridabad — plus a unit in Jhansi-Orchha (Uttar Pradesh) and, newly, Agra. By the end of FY26 it had crossed 3,200 beds of capacity across eight hospitals. The model is “cluster-based”: dense pods of hospitals in chosen catchments (Noida, Faridabad, now seeding Gurugram and a UP cluster), growing through a mix of greenfield builds, brownfield bed-additions on land it already owns, and acquisitions of running or stressed hospitals.

The economics rest on a few levers the calls return to constantly: occupancy (group ~68% in FY26, with mature Noida hospitals at 86–91%), ARPOB (average revenue per occupied bed per day, ~₹33,000 group-wide and rising ~7–10% a year), and payer mix — roughly 35% government (CGHS/ECHS/ESI on regulated rates), the rest split between cash and private insurance. Management has been deliberately “sanitising” the mix toward higher-paying segments and growing oncology (now ~10% of revenue, up from under 4% a few years ago).

Promoters (the Tyagi family) have seen their stake step down from 66.5% to 55.80% — not through selling for cash, but via a ₹625 crore QIP in December 2024 that funded acquisitions. The snapshot shows returns currently modest (ROCE ~12.4%, ROE ~10.4%) — depressed precisely because so much capital is tied up in beds not yet full — against a 5-year profit CAGR of ~57%. There is no dividend.

The Story So Far

The annual reports set the foundation; the four FY26 calls are where the bed-building strategy plays out quarter by quarter.

The setup (FY23–FY25, from the annual reports)

FY23’s report is thin — it was signed in June 2023, before the August IPO, so it reads as a pre-listing compliance document (consolidated revenue ₹520 crore, debt-to-equity a heavy 1.44). The investor story really begins in FY24: the ₹686 crore IPO let Yatharth repay ₹245 crore of debt (finance costs fell 93%, debt-to-equity collapsed to 0.09) and fund both organic capex and its first acquisition (Greater Faridabad). FY25 revenue grew 31% to ~₹880 crore, but the EBITDA margin slipped (26.8% → ~25%) and ROCE was “tempered” by start-up losses at new units — the central tension that would define FY26. Two acquisitions (a Delhi hospital via a SARFAESI auction, and a 60% stake in a second Faridabad hospital), funded by the December 2024 QIP, set up the ambition: ~3,000 beds by FY28.

Q1 FY26 (call of 6 August 2025) — the engine humming before the new beds

Yatharth opened the year with its “13th consecutive quarter of growth”: revenue ₹258 crore (+22%), EBITDA margin 25%, PAT ₹42 crore (+38%). The proof-point management leaned on was Greater Faridabad turning net-profit-positive within ~12 months of opening — evidence the ramp model works. It guided to ~30% FY26 revenue growth, a ~24% margin, and 8–10% annual ARPOB growth, and flagged the two big new hospitals (Delhi’s 300-bed Model Town in July, Faridabad Sector-20’s 400 beds in August) plus “at least one acquisition this year.” A ₹1,400–1,500 crore three-year capex plan was set out, alongside an overhang it kept tracking: an income-tax matter on a subsidiary.

Q2 FY26 (call of 14 November 2025) — the new-bed drag arrives, adjusted-margin holds

With two new hospitals open, the headline tension showed: reported EBITDA was flat-ish (margin would have been ~26.5% without the expansion), but adjusted EBITDA — stripping new-hospital losses — rose 35% to a 26.7% margin. Group occupancy dipped to 66% (the denominator just gained 700 beds). Management acquired Shantived Hospital in Agra (~250 beds, “EBITDA-positive from day 1”) and raised its ambition — from “3,000 beds by FY28” to roughly doubling capacity toward ~5,000 over 3–4 years. Two regulatory tailwinds entered the story: a CGHS rate revision (the first in over a decade, effective October 2025), guided at the time to add ~1% to FY26 EBITDA, and a GST cut on consumables. The income-tax overhang eased as a provisional asset attachment was lifted, and CRISIL upgraded the rating to A/Stable.

Q3 FY26 (call of 6 February 2026) — highest-ever EBITDA, the margin debate

The December quarter was the strongest yet: revenue ₹321 crore (+46%), record EBITDA (₹74 crore), adjusted EBITDA margin 29.2%. Existing hospitals grew 33%; the new ones contributed their first full quarter. Here management drew a clear line for analysts hoping for margin expansion:

“We are not targeting 28–29% even in 2–3 years… consolidated guidance is ~24–25% because of the constant drag of new beds. Ex-new-hospitals, margins run ~3–3.5% higher.” — paraphrasing Ashutosh Jha (Group Chief – Strategy) and Yatharth Tyagi (Whole-Time Director)

This is the deliberate trade-off at the heart of Yatharth: it will keep blended margins range-bound by always having immature beds in the mix, because the alternative — stopping the building — forgoes growth. Agra was integrated from 1 February 2026.

Q4 FY26 (call of 26 May 2026) — a record year, and a fourth cluster

FY26 closed at revenue ₹1,207 crore (+36%, beating the 30% guide), EBITDA ₹292 crore (margin 24.2% reported, 28.5% adjusted), PAT ₹170 crore, with a strong 98% cash conversion. Buyer of the year: a new under-construction super-specialty hospital in Central Gurugram (₹200 crore all-in, expected ARPOB above ₹50,000, operational around April 2027) — seeding a fourth cluster near the airport. The CGHS benefit was revised sharply up — now guided at ~5% of revenue and over 3% of EBITDA, versus the 2.5%/1.75% flagged in Q2 — which an analyst caught and management reconciled as full-quarter versus partial-implementation framing. Notably, the balance sheet shifted: net cash had thinned to ~₹115 crore after taking ~₹230 crore of debt to fund Agra, with the Gurugram outlay still ahead — the first real leverage since the IPO cleaned it up.

How the promises tracked:

• FY26 revenue ~30% → delivered +36%.
• FY26 margin ~24% → delivered 24.2% reported.
• Bed target → escalated through the year (3,000 by FY28 → ~5,000 in 3 years), capacity already >3,200.
• Agra “EBITDA-positive from day 1” → delivered, though ARPOB (~₹26–27k) came in below the ”>₹30,000” hoped at acquisition.
• Income-tax overhang → progressively de-risked (attachments lifted; “final leg,” resolution expected before Q2 FY27).
• Net cash → modest net debt → the one clear directional shift, as acquisitions outpaced internal cash.

Where Things Stand

As of the May 2026 call, Yatharth is executing a clear, repeatable playbook: buy or build beds in dense NCR clusters, ramp each hospital to break-even in ~15 months, and let mature units (Noida Extension’s ARPOB hit a record ₹47,800, up 23%) subsidise the gestation losses of the new ones. The reported margin will stay range-bound around 24–25% precisely because the strategy keeps feeding in immature beds — management has been explicit that this is a choice, not a ceiling. The tailwinds entering FY27 are real and largely regulatory: the CGHS/ECHS/ESI rate revision flowing through (now guided at ~5% of revenue), a maturing oncology business, and the Jewar (Noida International) airport — for which Yatharth is the exclusive hospital partner — feeding international and catchment demand. The watch-items are equally clear: occupancy at the two newest hospitals (Model Town 32%, Faridabad-20 52% at year-end) still has a long climb, government receivables remain slow (debtor days 112, targeting 90–95), and the balance sheet is just starting to lever up to fund Gurugram and the brownfield additions — with management insisting no equity raise is planned. The bet, for a stock at 44 times earnings, is that the beds fill faster than the cycle can punish.

The Four Checks

1. Quality and moat. A decent regional operator whose advantage is local density, not structure. The moat, such as it is, comes from being the tertiary-care supply in catchments where population outran hospitals: mature Noida units run at 86–91% occupancy, Noida Extension’s ARPOB hit ₹47,800 (up 23%), and the exclusive hospital partnership at the new Jewar airport adds a feeder nobody else has. But hospitals are a contestable trade — Delhi NCR has every large chain in the country, ~35% of revenue sits on government-regulated CGHS/ECHS/ESI rates (government receivables run near 200 days), and the demonstrated break-even-in-15-months ramp is a playbook, not a barrier. Local scale and execution, yes; a durable structural advantage, no.

2. Returns on incremental capital and runway. This is where the engine is hardest to read. Headline returns look mediocre — ROCE 12.4%, ROE 10.4%, with ROCE having slid from 27% in FY23 to 12% in FY26 — but that slide is the arithmetic of the strategy: roughly half the capital sits in beds not yet full. The mature-unit evidence is better — Greater Faridabad turned net-profit-positive within 12 months, Agra was EBITDA-positive from day one, adjusted EBITDA margin runs 28.5% at ~₹60–90 lakh of capex per bed — and the runway is genuinely long (3,200 beds heading toward 5,000, a ₹1,500 crore capex plan, NCR demand still outrunning supply). The honest read: moderate demonstrated returns with the promise of better ones if occupancy ramps deliver, in a business that will always carry a gestation drag because management refuses to stop building.

3. Capital allocation for the stage. Largely textbook for a build phase, with one structural cost. Every rupee goes back into beds: zero dividends in ten years of data, the ₹686 crore IPO first cleaned the balance sheet (₹245 crore of debt repaid, finance costs down 93%) before funding capex, and acquisitions follow a visible discipline — cluster-based, capex-per-bed targets, stressed assets bought through SARFAESI, Agra accretive from day one. The balance sheet is conservatively run: ₹264 crore of borrowings against ~₹1,780 crore of equity even after the FY26 spending surge, and management says no fund-raise is planned. The quibble is dilution — the ₹625 crore December 2024 QIP took promoter holding from 66.5% to 55.8%, so growth has been part-funded by selling pieces of the company while returns on the enlarged base are still around 12%. Rational, disciplined, but not yet self-funding. No buyback history to judge — at this stage there shouldn’t be one.

4. Price. Demanding. As of the June 2026 snapshot the stock trades at ₹840 — near its ₹890 high, against a ₹485 low — for a P/E of 46.2 and a market cap of ₹8,101 crore, on a business currently earning 12.4% ROCE and paying nothing out. The bull case is real (36% revenue growth, 57% five-year profit CAGR, CGHS rate tailwind, beds filling on schedule), but 46 times earnings already assumes the bed-building compounds without a stumble — a payer-mix shock, a slow ramp at Model Town (32% occupancy at year-end), or an acquisition that doesn’t turn would all be expensive at this multiple. You are paying today for hospitals that fill in 2028.

Sources

• Earnings-call transcripts read (4): Q1 FY26 (6 Aug 2025), Q2 FY26 (14 Nov 2025), Q3 FY26 (6 Feb 2026), and Q4/FY26 (26 May 2026). From screener/BSE-hosted filings.
• Annual reports read (high-signal sections + targeted full-text reads): FY23, FY24, FY25. The FY23 report predates the August 2023 IPO and is a thin pre-listing document; its operating detail was reconstructed from later reports’ restated comparatives.
• Financial snapshot: screener.in (consolidated, YATHARTH), logged-out session, fetched 2026-06-07. The snapshot does not disclose occupancy or ARPOB — those come from the concalls.
• Research dump: vault/Sources/Earnings/Yatharth Hospital & Trauma Care Services Ltd/ (_profile_digest.md, _concall_digest.md, _ar_digest.md, raw transcripts, annual-report sections, _snapshot.json, _manifest.json). Not published.